arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences,

FT Asia Pharma-Healthcare Summit

Singapore |
Speakers include:
Giles Platford

Giles Platford

Takeda Pharmaceuticals

Shankar Kaul

Shankar Kaul

Baxter Healthcare

Lisa Yeoh

Lisa Yeoh

Merck Sharp & Dohme


Adapting to regional trends in health economics and supporting investment

Healthcare in Asia is undergoing major transformation. Rapid economic growth and shifting epidemiological trends have led to increased expectations of both quality and affordability. Naturally, the agenda for growth and change in healthcare throughout Asia translates to an exciting but challenging business environment for the life sciences industry, especially for pharmaceutical and biotech companies looking to expand into the region.

The prospects for pharma-healthcare businesses in Asia are linked to a series of key questions: Which countries have the most industry-friendly approval processes? What are the various payment structures? What are the boundaries for relations with key opinion leaders? Where are the most attractive opportunities for investment and collaboration?

The FT Asia Pharma-Healthcare Summit takes place on 20 May 2015 in Singapore. Leading professionals and thought leaders will answer questions, propose solutions and discuss the future of the healthcare sector throughout the Asia-Pacific region.


fallback Add to my Calendar 05/20/2015 08:00:0005/20/2015 18:30:00trueFT Asia Pharma-Healthcare SummitAdapting to regional trends in health economics and supporting investmentHealthcare in Asia is undergoing major transformation. Rapid economic growth and shifting epidemiological trends have led to increased expectations of both quality and affordability. Naturally, the agenda for growth and change in healthcare throughout Asia translates to an exciting but challenging business environment for the life sciences industry, especially for pharmaceutical and biotech companies looking to expand into the region.The prospects for pharma-healthcare businesses in Asia are linked to a series of key questions: Which countries have the most industry-friendly approval processes? What are the various payment structures? What are the boundaries for relations with key opinion leaders? Where are the most attractive opportunities for investment and collaboration?The FT Asia Pharma-Healthcare Summit takes place on 20 May 2015 in Singapore. Leading professionals and thought leaders will answer questions, propose solutions and discuss the future of the healthcare sector throughout the Asia-Pacific region.VIEW OUR PHOTO GALLERYFT-Asia-Pharma-Healthcare-Summit4abd9613a0a6379047be19c8c1258471MM/DD/YYYY


Giles Platford

Giles Platford

President, Emerging Markets
Takeda Pharmaceuticals

Giles Platford became Takeda’s President of the Emerging Markets Business Unit in October 2014. He is responsible for leading the continued expansion of Takeda’s commercial activities in Asia (excl. Japan), Russia-CIS, Latin America and Middle East/Africa. He has been with Takeda since 2009. Most recently, he served as Head of Commercial Operations in the Emerging Markets region. Before that he was Head of the Middle East, Turkey, Africa (META) area where he restructured the business, generating 30% growth versus previous year for Fiscal Year 13. He has also served as General Manager of Takeda Brazil, where he led the successful acquisition of Multilab, a mid-sized company focused on branded generics and over-the-counter (OTC) products, positioning Takeda as one of the top 10 pharmaceutical groups in Brazil. He previously spent eight years in the pharmaceutical industry in Asia Pacific, assuming various Business Development, Commercial and General Management roles. A UK national, Giles Platford holds a BA Hons degree in Business and Marketing Management from Oxford Brookes University.

Shankar Kaul

Shankar Kaul

President and Region Head, Emerging Asia
Baxter Healthcare

Shankar Kaul joined Baxter in June, 2007 and has 25 years of commercial leadership and general management experience in the healthcare industry in the Asia Pacific region. Shankar began his healthcare career with C.R.Bard in 1990 and went onto hold various sales and marketing management positions in the South Asian Operations. In 1996 he joined Schneider, AG, a Pfizer subsidiary as Director, South Asia and following Schneider’s acquisition by Boston Scientific as Business Manager, Cardiovascular for South Asia. He moved to Singapore in 2001 as Director of Boston Scientific's South East Asian operations. In January 2004, he relocated to Shanghai as Country Director, Boston Scientific China and led the company's operations till May, 2007. Shankar served in Baxter as Vice President, Renal Asia Pacific for 4 years (Jun 2007 – May 2011) based in Shanghai. In June 2011, he relocated to Singapore following his appointment as GM Emerging Asia to oversee all of Baxter businesses. Following Baxter’s decision to spin off its biotech business as a separate company, Shankar has been recently appointed to lead the newly created Baxalta business for Asia and ANZ region, effective July 2015. Shankar holds an Honours degree in Economics from the University of Delhi.


Lisa Yeoh

Lisa Yeoh

Managing Director, Singapore/Brunei
Merck Sharp & Dohme

Lisa Yeoh is the Managing Director of Merck Sharp & Dohme in Singapore with experience spanning twenty years in the pharmaceutical, medical device and diagnostics industries. She has led organizations from launch preparation to turnaround, crisis and corporate reputation management, joint venture and partnership establishment. Ms Yeoh is a strong advocate for building and infusing market access capability into commercial strategy, and has introduced innovative approaches in out-of-pocket, single-payer and national health insurance markets. Her notable winning formula has taken MSD in Taiwan from the 6th to 3rd ranked pharmaceutical company in three years. Prior to MSD, she worked at Becton Dickinson in a variety of roles including regional marketing and country management. Having lived and worked in Asia Pacific and North America aside from undertaking projects in Russia and China, she brings a multicultural dimension to business leadership. She is a passionate champion of talent development and social responsibility with emphasis on diversity, sustainability and corporate integrity.

Amit Backliwal

Amit Backliwal

Vice-President, Technology and Services, China and South-East Asia
IMS Health

Amit Backliwal is Vice-President, Technology and Services, for China and South-East Asia at IMS Health. Currently based in Singapore, he is at the forefront of leading the company’s agenda in healthcare across a continuum of technology-based solutions, providing strategic advice on market-entry, growth, licensing, portfolio and launch excellence. Mr Backliwal has more than 15 years’ experience, achievements and leadership in consulting, sales and general management. Prior to his current role, he was General Manager of IMS Health South Asia, where he drove business growth in India and other South Asian countries. Since joining IMS Health in 2005, his leadership roles include Head of Management Consulting and General Manager of IMS Health Thailand. Before joining IMS Health, Mr Backliwal successfully launched Battaerd Mansley, an in-clinic effectiveness and measurement business in India. He has spoken at various healthcare conferences and has presented thought-leadership pieces for several organisations, including the Indian Cancer Society. Mr Backliwal has appeared on television and print media worldwide, sharing his views on access to affordable healthcare in emerging markets. He is co-author of a report, Understanding Healthcare Access in India, and a contributor to numerous white papers. Mr Backliwal holds a Bachelor of Pharmacy degree from the University of South Australia and an MBA from the University of Adelaide, Australia.

Karen Eryou

Karen Eryou

Senior Director, Corporate Compliance APAC

Karen Eryou has over fifteen years of international work experience in the pharmaceutical industry including Clinical Operations, Quality Assurance, Auditing and Inspections, as well as Medical Affairs. She has focused on business practices, ethics and compliance topics for the past seven years. Since 2011 Karen has been based in Shanghai where she was assigned to build the compliance function for UCB. Following the development and implementation of a comprehensive compliance program for the China team, she now leads the compliance program for the Asia-Pacific region.

Ajay Gautam

Ajay Gautam

Executive Director and Head of Collaborations, Asia-Pacific and Emerging Markets

Dr. Ajay Gautam is Executive Director and Head of Collaborations for Asia-Pacific and Emerging Markets for AstraZeneca’s IMED Biotech Unit based in Shanghai, China. He leads the development and implementation of AstraZeneca’s innovative medicines and early development strategy and collaborations in countries such as China, Australia, Korea, Israel, Russia, Turkey and Brazil. Prior to joining AstraZeneca, Ajay was the Co-founder and Managing Director of BionAbler, a healthcare investment firm focused on India, the Middle East and North Africa region. Previously, Ajay was Vice President, Corporate and Business Development at moksha8, a TPG backed Latin America-focused specialty pharma company. Prior to moksha8, Ajay was with the worldwide business development group at Pfizer, based in New York, working on various business development initiatives across commercial, manufacturing and R&D. He also managed the company’s R&D equity investment portfolio. Ajay holds a PhD in Biomedical Sciences and an MBA in Finance.

Christoph Glaetzer

Christoph Glaetzer

Vice President, Global Market Access

Christoph Glaetzer has more than 25 years’ global experience in the development and implementation of pharmaceutical market access and commercialization strategies. He has worked and lived in Europe, North America and Asia and is currently Vice President, Global Market Access at Janssen covering Health Economics, Pricing, Patient Reported Outcomes (PRO), Real-World Evidence (RWE) and Access Policy. Previous roles at Jansen include leading the regional Commercial and Access Strategy Organization in Asia-Pacific as well as being a representative at various international forums and initiatives (e.g. PhRMA, EFPIA, GHC, ISPOR, HTAi). Christoph is a champion of new access and pricing concepts to improve health outcomes globally. He is an International thought leader and speaker on commercial strategies, health care policy and pharmaceutical market access aspects.

Philippe Wolgen

Philippe Wolgen

Chief Executive Officer
Clinuvel Pharmaceuticals

Dr. Philippe Wolgen joined Australian-based biotechnology company Clinuvel in 2005. As CEO he has led a complete transformation of the company, taking a first-in-class molecule from proof of concept right through development to marketing approval for a neglected ultra-orphan disease.  He has been instrumental in raising $86 million since 2006 for the funding of the development program for SCENESSE®. He continues to lead Clinuvel’s commercial roll out of SCENESSE® and its expanded pipeline development through the Singaporean-based subsidiary VALLAURIX PTE LTD. The company has benefited significantly from Dr Wolgen’s strategic mindset, meticulous business execution, expertise in the life science sector and international finance experience. He holds an MBA from Columbia University NY and the London Business School. Having trained and practiced as a craniofacial surgeon, Dr Wolgen also holds an MD from the University of Utrecht, the Netherlands.

Allen Lai

Allen Lai

Regional Managing Director
ACT Genomics Singapore

Allen Lai is Regional Managing Director of ACT Genomics Singapore, strategising corporate development, planning and execution of cancer genomics clinical & research projects in South-east Asia. He holds high-profile roles as Advisor Board of ISPOR Asia Consortium, President of ISPOR Singapore and concurrently Senior Consultant, Ministry of Health and Social Welfare, Taiwan. Dr Lai previously was principal consultant at IMS Health Asia, director of the Institute of Health Economics & Management and academic director of MSc Management of Health Industries in ESSEC Business School. He received his PhD and MPA from Lee Kuan Yew School of Public Policy, National University of Singapore, MSc (Preventive Medicine) from National Taiwan University and MD from Chung Shan Medical Dental University, Taiwan.

Lance Little

Lance Little

Managing Director, Asia Pacific
Roche Diagnostics

Lance Little has been the Managing Director of Asia-Pacific Region for Roche Diagnostics since 2012. Prior to that he was the Managing Director of Roche Diagnostics India, where he was also the head of the wider Indian sub-region, which includes the neighbouring markets of Bangladesh, Bhutan, Nepal and Sri Lanka. Prior to this, his experience as Managing Director extends to both Roche Diagnostics Thailand and Roche Diagnostics New Zealand. Lance joined Roche in1995 in the technical support and management division of Boehringer Mannheim's Clinical Chemistry portfolio, before moving onto sales and marketing. As Head of Roche's Laboratory Systems Business in New Zealand from 2002 to 2008, Lance oversaw the strategic growth of its Centralized Laboratory as well as Roche Applied Science businesses. He was appointed Managing Director of Roche Diagnostics Thailand in 2008, before returning to New Zealand to take up the role of Managing Director in 2009. Lance started his career as a Medical Laboratory Scientist, specializing in Biochemistry at the Auckland Hospital Laboratory in New Zealand. Following this, he spent some time managing the Automation Laboratory at Diagnostic Laboratories in Auckland. Lance graduated from Auckland University of Technology with a degree in Medical Laboratory Science with specialization in Clinical Biochemistry.

Laurent Metz

Laurent Metz

Senior Director, HEMA and Clinical Research
Johnson & Johnson

Dr Laurent Metz is the Senior Director of Health Economics, Market Access and Clinical Research for Johnson & Johnson Medical Asia-Pacific. He has been working in Health Economics, Outcome Research and Reimbursement with Johnson & Johnson for the past 17 years in Asia-Pacific, Europe and in the United States. He has led the development and implementation of health economics and evidence generation strategies in most of the markets around the world and has been involved in multiple submissions to health technologies assessment bodies. With the Eucomed in Europe, he has contributed to the development of position papers on the specificities of medical devices evaluation. He was the Chairman of the Eucomed Funding and Reimbursement task force. Laurent is a Medical Doctor graduated from the University of Medicine of Nancy, France. He has a MBA from HEC Business School, Paris, France. He completed the Advanced Strategic Management program at IMD, Lausanne (Switzerland), the executive course in Health Economics at the Stockholm School of Economics and Value Measurement for Health Care program by Harvard Business School. Laurent is member of the International Society of Health Economics & Outcome Research and a member of the Society for Medical Decision Making.

Mark Lee

Mark Lee

Senior Vice President, Corporate Finance and Development
Hutchison China MediTech

Mark Lee focuses on Chi-Med’s strategic management, corporate operations, investor relations and supporting its numerous R&D alliances. This includes leading or assisting with the project management of certain clinical programmes, coordination of R&D leadership, and R&D financial management. Prior to joining Chi-Med in 2009, Mr Lee was with Credit Suisse in the United States and Europe, where he was involved in the execution and origination of mergers, acquisitions, public and private financings, and corporate strategy for pharmaceutical, life science and healthcare companies such as AstraZeneca, Bristol-Myers Squibb, Genzyme and Syngenta, amongst others. Mr Lee received his Bachelor of Engineering in Biochemical Engineering with First Class Honours from University College London, where he was awarded a Dean’s Commendation. He also received a Master of Business Administration from the Massachusetts Institute of Technology, Sloan School of Management.

Tomotaro Nagakawa

Tomotaro Nagakawa


Mr Nagakawa is a lead partner in Deloitte Japan’s Life Sciences practice, assisting major Japanese and multi-national pharmaceutical / medical device companies. He has over 16 years of experience in the industry with special emphasis on strategy and execution, including development of corporate and overseas market entry strategies.

Meaghan Gibbs

Meaghan Gibbs

Information Fulfillment Ltd

As Director of Information Fulfillment Ltd, Meaghan Gibbs has worked with health technology companies globally to develop highest-value pricing and market access strategies using evidence-based approaches in Asia. Prior to founding Information Fulfillment Ltd, Ms Gibbs was Practice Leader for Pricing and Market Access in Asia at IMS. While at IMS, she was also involved in conducting economic evaluations for the Australian Pharmaceutical Benefits and Medical Services Advisory Committees. Before joining IMS, Ms Gibbs worked for the Massachusetts Executive Office of Health and Human Services where she represented the Deputy Director's Office on US Medicaid initiatives. She also worked for the Massachusetts Legislature's Committee on Health Care where she specialized in the area of health care financing. Ms Gibbs graduated from the London School of Economics with a Bachelor’s in Government and later obtained a Master’s in Health Policy, Planning and Financing from the LSE and the London School of Hygiene and Tropical Medicine.

Benjamin Seet

Benjamin Seet

Executive Director, Biomedical Research Council
Agency for Science, Technology and Research, Singapore

Dr Benjamin Seet is the Executive Director of the Biomedical Research Council, Agency for Science, Technology and Research (A*STAR) in Singapore. Prior to joining A*STAR, he served as Chief of the Singapore Armed Forces Medical Corps; Chief Army Medical Officer; and Chief Medical Officer of the United Nations Department of Peacekeeping Operations in New York. Other appointments held included Visiting Consultant to Singapore’s Ministry of Health; Director, Agri-food and Veterinary Authority; Director, Health Promotion Board; and Chairman, InVivos Pte Ltd. He currently serves on the Board of the National Medical Research Council and on a number of inter-agency committees.

Dr Seet earned a Bachelor’s degree in Medicine and Surgery and a Master’s in Medicine (Ophthalmology) from the National University of Singapore, as well as a Fellowship from the Royal College of Surgeons in Edinburgh, and a Master of Public Health from Johns Hopkins University.

Benjamin Shobert

Benjamin Shobert

Senior Associate, International Health
The National Bureau of Asian Research

Ben is the Managing Director of Rubicon Strategy Group. He is also a Senior Associate for International Health at NBR, where he advises and contributes to NBR research programs on international health in Asia. In addition, Ben is a columnist for Forbes, where he writes about healthcare and aging in Southeast Asia. Previous to Forbes, for more than six years, Mr. Shobert wrote a column for the Asia Times on US-China trade and economic policy with a particular focus on how relations between the two countries were impacted after the 2008 financial crisis. His works have been featured at CNBC, China Business Review, Forbes China, and Harvard Asia Quarterly. Ben is also a contributor to the new book, The Global Obama. Mr. Shobert serves on the advisory boards of the Indiana University’s Research Center on Chinese Politics and Business and the IAHSA-China (The Global Aging Network). He is a member of the National Committee on United States–China Relations and the Pacific Council on International Policy. He holds an MBA from Duke University’s Fuqua School of Business.

Raman Singh

Raman Singh

President, Emerging Markets

Based in Singapore, Raman Singh was appointed President of Mundipharma Asia Pacific, Latin America, Middle East and Africa, in October 2011. Mr Singh oversees all aspects of the Mundipharma businesses across these territories, which operate as a network of independent companies and leaders in pain management. Prior to this appointment, Mr Singh was the Vice-President of Commercial Operations for Emerging Markets at GlaxoSmithKline, based out of London, where he was in charge of overseeing all aspects of the brand’s Commercial operations across its emerging markets. He has previously held positions in Abbott as the Regional Director in Australia and New Zealand, and General Manager for Korea. He has also held various sales, marketing and strategy positions in Bayer. Mr Singh holds an MBA from Thunderbird, the American Graduate School of International Management.

BT Slingsby

BT Slingsby

Chief Executive Officer
Global Health Innovative Technology Fund

BT Slingsby, MD, PhD, MPH, is Executive Director and CEO of the Global Health Innovative Technology (GHIT) Fund. Previously, he was Director for Global Access Strategies for Eisai & Co. and Executive Director for Eisai-Quintiles World Health Initiative. He has published over 40 peer-reviewed articles on health in Japanese and American literature and co-authored the first textbook on bioethics in Asia. He is a Research Fellow at several major Japanese medical schools. He earned his MD at George Washington, his PhD at the University of Tokyo School of Medicine, and his MPH at Kyoto University School of Medicine. He is a former professional triathlete and member of the United States World Cup Team.

Amit Varma

Amit Varma

Managing Partner
Quadria Capital

Dr. Amit Varma has over 20 years of Private Equity, strategic and operational leadership and board level experience in healthcare organizations across USA, Asia and Australia. He is Managing Partner of Quadria Capital, a $300 million healthcare focused private equity fund that invests in healthcare sector across South and Southeast Asia. He is also a renowned critical care medicine physician and continues to practice on a part-time basis. Amit previously spearheaded India Build Out Fund, a $100m Healthcare and Education focused domestic private equity fund. He has also served in various other roles including managing and operating procurement of medical supplies, strategy and quality of healthcare organizations, and recruitment of key physicians in organizations such as Fortis, Narayana Hrudayalaya Private Ltd. and the Manipal Heart Foundation. Amit is on the editorial boards of various healthcare and management groups and societies. Amit has an M.D. from the University of Delhi, India, super-specialty medicine training from the University of New York and University of Pittsburgh, USA.

Joshi Venugopal

Joshi Venugopal

Country Head, Singapore and Asian Emerging Markets

Joshi Venugopal is currently serving as the Country Head of Novartis for Singapore and Asian Emerging Markets. Prior to this role he served as the Country Head for Panama and West Indies and before that as the Assistant to the Chairman of Novartis. Joshi has a broad experience in the pharmaceutical industry and has served in various functions including research, strategy, marketing, finance and medical affairs. Joshi has lived in many countries including Switzerland, USA, India, Panama, UK, Ireland and Singapore and during this process developed a strong interest in comparing healthcare systems around the world. Research conducted by Joshi and colleagues that compared healthcare systems around the world has shed new light on what can be done to improve quality and reduce costs. His recent talk “The Biggest Myth in Healthcare” was delivered at TEDx. He has published several articles including in The Financial Times and The Globalist. Joshi holds a PhD in Cell Biology from the University of Basel (Switzerland) and is an alumnus of Harvard Business School (USA).

Prabhu Vinayagam

Prabhu Vinayagam

Managing Director, Asia-Pacific Office
Joint commission International

Dr. Prabhu Vinayagam assumed the role of managing director of the Singapore-based Asia- Pacific Office of Joint commission International in July 2014. He is an accomplished C- suite executive with experience in health care strategy and innovation, and draws upon his background as a medical and surgical clinician. In his current role, Prabhu is responsible for regional and country-level strategy and business development for JCI’s advisory services, accreditation, and education units in the Asia-Pacific region. He also works to develop and strengthen strategic relations with international organisations, ministries of health, and leading academic medical centres and hospitals in the region. Prabhu was instrumental in developing an infection control audit successfully used by hospitals in China, India, Indonesia, the Philippines, South Korea, Singapore, and Australia. Prabhu is a Medical graduate from India and a MBA from Singapore.

Alain Bouckenooghe

Alain Bouckenooghe

Associate Vice President and Regional Head of Clinical R&D and Medical Affairs, Asia Pacific
Sanofi Pasteur

Dr. Alain Bouckenooghe oversees the regional medical affairs management of Sanofi Pasteur’s licensed vaccines portfolio. He is also in charge of directing Sanofi Pasteur’s new vaccine developments in the Asia-Pacific region. This includes the establishment of a regional R&D platform as well as strategic regional input to all aspects of new vaccine development relating to regulatory strategy, business affairs, scientific affairs and public policy within the region. Prior to joining Sanofi Pasteur USA in December 2006, Dr. Bouckenooghe led the rotavirus vaccine clinical development program at GlaxoSmithKline Biologicals. He also previously held the position of Director of Regulatory Affairs with MSD Europe and worked for several years as the General and District Medical Officer at the Ministry of Health in Zambia. Dr. Bouckenooghe obtained his MD at the Catholic University of Leuven, Belgium and his Master’s Degree in Public Health (MPH) at University of Texas-School of Public Health, Houston, Texas, USA.



Andrew Ward

Andrew Ward

Energy Editor
Financial Times

Andrew Ward is the FT’s Energy Editor, leading global coverage of the oil and gas industry, power generation and related policy and geopolitical issues. Before taking up his current role in June 2016, Ward was Pharmaceuticals Correspondent, reporting on life sciences, medical technology and healthcare.

Prior to this, Ward was UK News Editor, leading the news desk responsible for the FT’s coverage of UK politics, policy and economics. Previously, Ward served the FT in a number of foreign reporting roles. He was the Nordic bureau chief responsible for coverage of eight countries – Sweden, Norway, Finland, Iceland, Denmark and the three Baltic states of Latvia, Estonia and Lithuania.

Ward has also been the White House correspondent, during which role he covered the George W. Bush administration and the 2008 presidential election campaign. Before moving to Washington, Ward covered business and politics in the US south-east as Atlanta Correspondent. Between 2001 and 2004, he served as Seoul Correspondent, reporting on North and South Korea.

Ward joined the FT in 1999 as a graduate trainee in London and was appointed Media Correspondent in 2000. Ward received his B.A. in Politics and Modern History from the University of Manchester, UK.

Follow Andrew Ward on twitter: @andrew_ward1


Reynold W. (Pete) Mooney

Reynold W. (Pete) Mooney

Global Managing Director, Life Sciences and Health Care

Reynold W. (Pete) Mooney is a senior strategy consulting principal and is currently the Global Managing Director for the Life Sciences and Health Care industry group for Deloitte Touche Tohmatsu Limited (Deloitte). In this role, he is responsible for building practice capability around the world, ensuring consistent service offerings across lines of business, and works closely with Deloitte’s network of member firms in serving clients, governments, Ministries of Health, NGOs, and other constituencies. He is also a principal in Deloitte’s US member firm. Mr Mooney is consulted frequently on global health issues and by pharmaceutical, biotechnology, medical device and other companies that supply the industry. He is a frequent speaker and author on industry topics. Over the course of his thirty-five year career with Deloitte member firms, he has served a number of very significant client relationships across a diverse set of issues, industry sectors, geographies and cultures. A manufacturing professional by background, his approach to strategy is grounded in solid operations management concepts. He gravitated to the life sciences sectors while working with several European chemicals conglomerates in the early 1990s, and currently works with a diverse set of leading life sciences and health care clients globally in both the public and private sectors.

Mr Mooney received a BA from Washington & Jefferson College, where he currently serves as a Trustee, and an MBA. from the Katz School of Business, University of Pittsburgh.

Why Attend?

  • Hear thought leaders describe the health economics environment throughout Asia
  • Discuss the implications of universal healthcare coverage for different stakeholders
  • Learn about regulatory and financial challenges for market access in different countries
  • Meet representatives from government agencies with the power to influence policy
  • Debate best practises for interaction between pharma and healthcare providers
  • Explore opportunities for investment in innovation and clinical development

Agenda - 20th May

  • 8:00am
    Registration and refreshments
  • 9:00am
    Chairman's opening remarks

    Andrew Ward, Pharmaceutical Correspondent, Financial Times

  • 9:10am
    Opening keynote address: The emerging challenges and opportunities for healthcare in Asia

    The keynote presentation will focus on how standards of healthcare in Asia are being affected by different factors including emerging affluence in markets like China and India, increased prevalence of westernized diseases, higher levels of government investment into healthcare (vs. GDP and per capita) and parallel government efforts around cost containment.

    Giles Platford, President, Emerging Markets, Takeda Pharmaceuticals

  • 9:40am
    Panel: The changing healthcare needs of populations in Asia

    In a rapidly developing part of the world, what are the standout epidemiological trends in health? How are countries responding to increased demand for non-communicable disease treatments? How is the consumer healthcare market changing? What are some of the biggest gaps in demand for treatment and how can businesses access the market? How can businesses work with communities to identify and meet changing healthcare needs? What is the role of vaccines in the public health agenda and how is this shaping healthcare delivery systems across Asia? What should be the role of the public sector in growing Public Private Partnerships that ensure effective healthcare delivery to meet growing needs of the public? 


    Allen Lai, Director, Institute of Health Economics and Management, ESSEC Business School
    Benjamin Seet, Executive Director, Biomedical Research Council, Agency for Science, Technology and Research, Singapore
    Prabhu Vinayagam, Managing Director, Asia-Pacific Office, Joint commission International
    Alain Bouckenooghe, Associate Vice President and Regional Head of Clinical R&D and Medical Affairs, Asia Pacific, Sanofi Pasteur

    Moderated by Andrew Ward, Pharmaceutical Correspondent, Financial Times

  • 10:30am
    Panel: Achieving sustainable access to healthcare across Asia

    As governments in Asia make commitments on healthcare provision for populations, what are the economic benefits of different healthcare systems? How do the roles of stakeholders change within a universal healthcare model? Which Asian countries have implemented robust and efficient national healthcare systems, and which ones are struggling to meet their universal healthcare goals? What are the biggest challenges in making the transition from an out of pocket system to universal healthcare? How can stakeholders work together to ensure long-term financial sustainability of universal healthcare systems?


    Christoph Glaetzer, Vice President, Strategic Marketing and Market Access, Asia Pacific, Janssen Pharmaceutica
    Lance Little, Managing Director, Asia Pacific, Roche Diagnostics
    Amit Backliwal, Vice President, Technology and Services, IMS Health
    Meaghan Gibbs, Director, Information Fulfillment Ltd

    Moderated by Pete Mooney, Global Managing Director, Life Sciences and Health Care, Deloitte

  • 11:20am
    Morning refreshments
  • 11:40am
    View from the top: Exploring unchartered territories in Asia

    Hear a leading pharma company executive share insights into the risks and rewards of expanding into Asia.


    Joshi Venugopal, Country Head, Singapore and Asian Emerging Markets, Novartis

  • 12:10pm
    Panel: How commercially durable is Asia’s healthcare and life sciences industry?

    Many global companies are setting up R&D activities in Asia to take advantage of the region’s growing talent pool. Asia’s home-grown healthcare industry is also growing rapidly, but challenges include rising labour costs and regulatory reform. How are Asian companies making the transition from generics manufacturers to innovative enterprises?Why are so many private companies going public? How big is the biosimilars market in Asia and who is investing in it? What are governments doing to help businesses and what do they expect in return? What are the new potential risks for foreign firms looking to expand into Asian emerging markets? Is M&A an attractive and viable option for these players?


    Ajay Gautam, Executive Director and Head of Collaborations, Asia-Pacific and Emerging Markets, AstraZeneca
    Mark Lee, Senior Vice President, Corporate Finance and Development, Hutchison China MediTech
    Vivek Pathak, Regional Director, Asia and the Pacific, International Finance Corporation
    Amit Varma, Managing Partner, Quadria Capital

    Moderated by Pete Mooney, Global Managing Director, Life Sciences and Health Care, Deloitte

  • 1:00pm
    Networking lunch
  • 2:15pm
    Afternoon keynote address: Reducing access barriers to critical therapy

    While demand for critical therapy rises, patient access barriers to care are multifold, particularly in emerging economies. This speech will highlight how Baxter Healthcare navigates this complex environment, and how it targets actions to reduce barriers to peritoneal dialysis care in the Asia Pacific region.

    Shankar Kaul, President and Region Head, Emerging Asia, Baxter Healthcare

  • 2:45pm
    Panel: Market access strategy – the key to success in Asia

    While various associations in different Asian markets have their own codes of conduct and practice covering the development, marketing and sale of pharmaceutical products and medical equipment, cross-border standards vary significantly, with licensing and regulation being time-consuming and costly. How will the harmonisation schemes proposed by the ASEAN Economic Community help to eliminate present cross-border trade barriers? What will these new rules of engagement and industry standards mean for governments, providers and patients? How is pricing policy affecting product availability in different Asian markets? What must be done in order for more innovative products to enter the market? What are the benefits and disadvantages of risk-sharing agreements?How do existing market access protocols in China reflect the unique needs of their healthcare system? Is there potential for an EMA/FDA type body that covers whole Asia-Pacific region? To what extent will the demands of regulators here align with those in the US or Europe?


    Lisa Yeoh, Managing Director, Singapore and Brunei, Merck Sharp & Dohme
    Laurent Metz, Senior Director, HEMA and Clinical Research, Johnson & Johnson
    Benjamin Shobert, Senior Associate, International Health, The National Bureau of Asian Research
    Tomotaro Nagakawa, Partner, Deloitte

    Moderated by Andrew Ward, Pharmaceutical Correspondent, Financial Times

  • 3:45pm
    Afternoon refreshments
  • 4:05pm
    Panel: Building and maintaining positive relationships with stakeholders

    Standards for interaction between industry, payers, providers and patients need to be clearly defined, but how should those standards be defined? What do healthcare providers in Asia expect from businesses and vice-versa? What should be the rules for collaboration between industry and healthcare providers? How can industry appropriately communicate value to providers that operate in multiple markets with different payment structures? How should practitioners and patients be educated about conditions and treatment options?


    Raman Singh, President, Asia Pacific, Latin America, Middle East and Africa, Mundipharma
    BT Slingsby, Chief Executive Officer, Global Health Innovative Technology Fund
    Karen Eryou, Senior Director, Corporate Compliance APAC, UCB
    Philippe Wolgen, Chief Executive Officer, Clinuvel Pharmaceuticals

    Moderated by Andrew Ward, Pharmaceutical Correspondent, Financial Times

  • 4:55pm
    Closing remarks

    Andrew Ward, Pharmaceutical Correspondent, Financial Times

  • 5:00pm
    Networking drinks

Who Attends?

FT Live pharmaceutical events attract senior corporate decision-makers and thought leaders from around the world including Chairmen, CEOs, CFOs, Presidents and Managing Directors at: 

  • Pharmaceutical and biotechnology companies
  • Medical devices, medical technology, instrumentation and diagnostics companies 
  • Health insurers, government and private health service providers 
  • Regulatory agencies and health technology assessment bodies
  • Investment banks and private equity firms
  • Patient representative organisations, health NGOs and social media consultancies
  • Renowned academic institutions


  • Abbott 
  • Actavis 
  • AstraZeneca 
  • Covance 
  • Deloitte 
  • Eli Lilly 
  • Ernst & Young 
  • European Medicines Agency 
  • Ferring Pharmaceuticals
  • GE Healthcare 
  • GlaxoSmithKline 
  • Johnson & Johnson 
  • MedImmune
  • Medtronic
  • Merck 
  • NHS England 
  • Novartis 
  • Pfizer 
  • Quest Diagnostics 
  • Quintiles 
  • Roche 
  • Sandoz 
  • Sanofi 
  • Shire 
  • Takeda 
  • Teva 
  • University of Oxford


80 Middle Road
Singapore 188966


Tel: +65 6338 7600


Hotel Booking

InterContinental Singapore

Conference Rate for FT Asia Pharma-Healthcare Summit

Special conference rates are available at InterContinental Singapore. 

To book your accommodation, CLICK HERE.

All reservations will be under guest individual account.

Deluxe Room

Single Occupancy at S$365.00++ per room per night

(Inclusive of Buffet Breakfast for one (1) person and 24-hours in-room internet)

Double Occupancy at S$395.00++ per room per night

(Inclusive of Buffet Breakfast for two (2) person and 24-hours in-room internet)

The above rates are subject to 10% service charge and thereafter prevailing taxes, which are currently at 7%.


Organiser (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

Associate Sponsors (2)

Information Fulfillment Ltd. (IFL) provides health economic solutions for the Asia region. Since 2007, the consultancy has worked with clients to identify highest-value opportunities and develop the most effective strategies to take health-related technologies from registration to reimbursement. With expertise in health technology assessment, pricing and market access, health care policy and training and development in health economics, IFL provides clients with evidence-based solutions that demonstrate the value of their products in Asia. IFL maintains offices across the Asia region. IFL’steam is comprised of consultants with country-specific knowledge of pricing and reimbursement systems in Asia working alongside seasoned specialists with years of industry experience. 

About IMS Health
Creating Connected Solutions for Better Healthcare Performance

IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. Our 7,500 services experts connect configurable SaaS applications to 10+ petabytes of complex healthcare data in the IMS One™ cloud platform, delivering unique insights into diseases, treatments, costs and outcomes. The company’s 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.

As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at

Supporting Media Partners (12)

Asian Scientist Magazine is a print and online magazine that covers breaking R&D news and feature stories from the Asian scientific and medical community. The magazine is dedicated to providing healthcare professionals, researchers, government agencies, educators and students with timely, close-to-the-scene information from Asia.

About BioSpectrum Asia

BioSpectrum is an integrated B2B media platform for the bioscience industry in the Asia Pacific region. It engages its readers from pharma, lifescience, biotech and medtech industry segments through its media products and services at a daily, fortnightly and monthly frequencies across countries, in Asia. Given its sharp reportage focus on the Asia Pacific region, it is also a one-stop information hub on Asia bioscience industry for readers from US and Europe.

Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries. There are currently over 33,000 company profiles on the Biotechgate database.

Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.

CanBiotech is an open innovation platform for the biotechnology and pharmaceutical industries. Source new partners through the CanBiotech portal, participate in our open innovation training workshops in partnership with BioEndeavor and engage CanBiotech and its network of partners to enable open innovation in your organization.

The Emerging Market Investor's Association (EMIA) connects investors with reputable investment professionals, research, education and news, increasing confidence and transparency within emerging markets. For investment professionals, we create enhanced brand awareness that deliver tangible opportunities for business growth.

For investors, EMIA is an objective, comprehensive and unbiased source of expert, on­the­ground information, daily news and in­depth analysis. In short, EMIA is the world’s first and only not­for­profit Emerging Market organization, dedicated to advancing the industry as a whole and representing the combined interests of investors and investment professionals across asset classes.

fDi Intelligence is the largest FDI centre of excellence globally. Specialising in all areas relating to foreign direct investment and investment promotion, the full suite of services includes: location advertising to generate brand awareness; industry-leading intelligence tools to develop FDI strategies and identify potential investors; and tailored FDI events and investor roundtables to meet target companies and generate business leads. Products within the portfolio include fDi Markets, a database tracking crossborder greenfield investment on a real-time basis; fDi Benchmark, a database which benchmarks global locations on their attractiveness to foreign investors; and fDi Magazine.

The Voice of Pharmaceutical Manufacturing

PharmaAsia, published by Contineo Media, is the authoritative source of information for pharmaceutical manufacturers in Asia. It provides the most compelling and in-depth industry information about the latest trends and technologies of all aspects in drug manufacturing. Printed quarterly, the magazine is read by over 6,000 qualified decision-makers in the region. In addition, is a free-access website that provides daily news updates and the latest happenings in the industry complemented by specialised knowledge channels.

Pharmafocus is a monthly newspaper for the UK and European pharmaceutical and biotech industry that provides high-quality news, analysis and industry intelligence.

Our dedicated team of journalists update the website, newspaper and e-newsletters daily with the latest international news and features. Pharmafocus covers a broad range of issues affecting the industry including all areas of the drug lifecycle, with a strong focus on drug development, clinical trials, sales and marketing, and market access. Launched in 1998 and requested by a readership of 14,000 senior industry professionals, Pharmafocus is the most-read and respected pharma news source in the marketplace.

Pharma Focus Asia is a bi-annual magazine from Ochre Media Pvt. Ltd. Pharma Focus Asia covers important issues and trends shaping the future of the Pharma industry across Asia and rest of the world. It is the leading Pharma title in print as well as digital versions serving the information needs of key executives from the world’s leading pharmaceutical companies.

Pharmalicensing is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide.Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world.Pharmalicensing, and its sister service Medical Device Licensing ( are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.

PharmaVOICE magazine, reaches more than 41,000 qualified subscribers and 100,000 users with its digital edition. PharmaVOICE is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry. PharmaVOICE provides readers with insightful and thought-provoking commentary in a multiple-perspective format through forums, topics, and articles covering a range of issues from molecule through market. PharmaVOICE subscribers are also kept abreast of the latest trends and information through additional media resources, including Social Media, WebLinx Interactive WebSeminars, Podcasts, Videocasts, White Papers, E-Surveys and e-Alerts.

About Spurwing Communications

Spurwing Communications prides itself on being a leading public and investor relations agency dedicated solely to working with healthcare sector clients.  We provide strategic counsel to corporations, Boards, senior decision makers and executives on critical communications programmes and challenges. From our Asia regional office in Singapore, Spurwing’s senior team provides cross-border comprehensive financial and corporate communications advice to some of the world’s most prominent and innovative healthcare corporations around-the-clock.

Official Newswire Partner (1)

PR Newswire is the premier global provider of news release distribution and multimedia platforms that enable marketers, corporate communicators, public relations officers and investor relations professionals to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry in 1954, PR Newswire today provides end-to-end solutions to produce, optimize and target content – from rich media to online video to multimedia – and then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world's largest multi-channel, multi-cultural content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire enables the world's enterprises to engage opportunity everywhere it exists. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and the Asia-Pacific region, and is a UBM plc company. Email to know more.

Contact Us

Delegate Booking And Registration Enquiries
Pamela Lam
Conference Executive
Sponsorship Opportunities
Gigs Thoukidides
Senior Business Development Manager EMEA
Speaking Opportunities
Ciaran Larkin
Senior Content Editor
Media Partner And Press Enquiries
Vian Fu
Marketing and Campaign Executive